ClinicalTrials.gg
CompletedNCT04604704Updated Jan 25, 2023

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

A Phase 2 interventional study of Naltrexone and NAD+ in Covid19, Long COVID-19 and Post-COVID-19 Syndrome, sponsored by AgelessRx. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-25.

Primary conditionPost-Acute COVID-19 SyndromeRegistry: COVID-19ReclassifiedWhy we changed it
Registry
COVID-19 — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Acute COVID-19 Syndrome
Why
  1. The study's listed conditions name Post-Acute COVID-19 Syndrome, a narrower term within COVID-19.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AgelessRx · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Enrollment
98th of 155
36 · median 52
Started
2021
with 18 others
Phase 2
47 of 194
10 open now
Registered
3rd of 194
by date

Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 98th largest by enrollment of the 155 interventional ones that give a count, is one of 19 that started in 2021, is one of 47 in phase 2, and was the 3rd registered.

Post-Acute COVID-19 Syndrome

605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

62 of the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.

Read the detailed description

This interventional pilot study will assess the use of low dose naltrexone (LDN) and NAD+ for the treatment of patients with post-COVID-19 syndrome (long-COVID-19).

Patients with a positive test for SARS-CoV-2 1-4 months before enrollment will be included. Subjects should have self diagnosed post-COVID19 syndrome and experiencing persistent fatigue since positive test. Patients will be screened using the fatigue survey and cases with a moderate to severe score will be included.

Patients will receive LDN and NAD+ treatment for 12 weeks. In this study, fatigue and quality of life will be assessed using validated surveys. Surveys will be conducted at baseline (at the time of enrollments, before treatment), and at 2, 4, 8, and 12 weeks. The improvement of scores from baseline levels will be assessed.

03

Conditions studied

  • Covid19
  • Long COVID-19
  • Post-COVID-19 Syndrome

Browse trials for

Keywords

  • COVID-19
  • Long COVID-19
  • Post-COVID-19 syndrome
  • naltrexone
  • NAD
  • Nicotinamide adenine dinucleotide
  • low dose naltrexone
  • LDN
04

In context

Post-Acute COVID-19 Syndrome Reclassified

605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's enrollment of 36 is below the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

AgelessRx is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is COVID-19. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any ethnicity
  • Adequate cognitive function to be able to give
  • Technologically competent to complete web forms and perform video calls with the PI
  • Positive PCR test (polymerase chain reaction) result for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) 1-4 months before enrollment
  • A fatigue score above 9 in the Chalder Fatigue scale upon enrollment
  • Willing to fill out regular questionnaires
  • Willing to use LDN and NAD patches

Exclusion criteria

Exclusion Criteria:

  • kidney, heart, Hepatic impairment as determined by clinical judgement
  • Taking opioid analgesics, or undergoing treatment for opioid addiction
  • Opioid dependence or withdrawal syndrome
  • Known sensitivity to naltrexone
  • Suspected or confirmed pregnancy or breastfeeding
  • Known issues with using iontophoresis patches
  • Active cancers
  • Enrolled in another trial
  • Current users of LDN or NAD+
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Treatment with LDN and NAD+

    LDN will be used at a dosage of 4.5 mg/day, which will be taken orally in the form of tablets. NAD+ will be administered using the IontoPatch iontophoresis patch containing 400 mg of NAD+ solution which is worn on the skin for 4-6 hours once per week.

    Drug: Naltrexone · Dietary Supplement: NAD+

Interventions

  • Naltrexone at 4.5 mg/day

    Also known as: Low dose Naltrexone (LDN)

  • Dietary supplementNAD+

    NAD+ will be applied using iontophoresis patches. The patches will be provided by ready-made NAD+ solutions (400 mg) to be applied to the positive electrode of the patch and saline to the negative electrode. The patch is powered by a self-contained battery, producing an electric current to facilitate NAD+ absorption through the skin into the blood. Patches are worn for 4-6 hours once a week.

    Also known as: Nicotinamide adenine dinucleotide

07

What researchers measure

Primary outcomes

  1. Reduction of fatigue in post-COVID-19 syndrome by treatment with LDN and NAD+

    Reduction of fatigue score from baseline as measured by the Chalder fatigue scale in post-COVID-19 syndrome by treatment with LDN and NAD+. The Chalder scale has a minimum value of 0 and a maximum value of 33, and the higher the score the more severe the fatigue symptoms are.

    Time frame: 12 weeks

Secondary outcomes

  1. Improvement of quality of life in post-COVID-19 syndrome by treatment with LDN and NAD+.

    Improvement of quality of life scores from baseline as measured by the short form-36 (SF-36) survey in post-COVID-19 syndrome by treatment with LDN and NAD+. The SF-36 survey provides scores between 0-100 with lower scores representing more disability.

    Time frame: 12 weeks

08

Study locations

1 site
  • AgelessRx
    Ann Arbor, Michigan 48104, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jan 2023, 23 months.

Of 63 phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2020
First posted
Oct 27, 2020
StartActual
Jan 28, 2021
Primary completionActual
Jan 23, 2023
CompletionActual
Jan 23, 2023
Last update
Jan 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04604704
Lead sponsor
AgelessRx
Responsible party
Sponsor
First posted
Oct 27, 2020
Start date
Jan 28, 2021
Primary completion
Jan 23, 2023
Completion
Jan 23, 2023
Last update
Jan 25, 2023

Study contacts

Sajad Zalzala, MD
study director · AgelessRx
Sajad Zalzala, MD
principal investigator · AgelessRx

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion